A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2

U
Utpal Dave, MD

Primary Investigator

Overview

A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    cancer,relapse peripheral T-cell lymphoma
  • Age: Between 18 Years - 100 Years
  • Gender: All


Updated on 09 Mar 2024. Study ID: 11582
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center